- Home
- SRZN vs UBX Comparison
SRZN vs UBX Comparison
Compare SRZN & UBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRZN
- UBX
- Stock Information
- Founded
- SRZN 2015
- UBX 2009
- Country
- SRZN United States
- UBX United States
- Employees
- SRZN N/A
- UBX N/A
- Industry
- SRZN Medicinal Chemicals and Botanical Products
- UBX Biotechnology: Pharmaceutical Preparations
- Sector
- SRZN Health Care
- UBX Health Care
- Exchange
- SRZN Nasdaq
- UBX Nasdaq
- Market Cap
- SRZN 33.0M
- UBX 36.9M
- IPO Year
- SRZN N/A
- UBX 2018
- Fundamental
- Price
- SRZN $11.20
- UBX $1.94
- Analyst Decision
- SRZN Strong Buy
- UBX Strong Buy
- Analyst Count
- SRZN 2
- UBX 2
- Target Price
- SRZN $38.50
- UBX $7.00
- AVG Volume (30 Days)
- SRZN 28.0K
- UBX 203.3K
- Earning Date
- SRZN 04-09-2025
- UBX 04-14-2025
- Dividend Yield
- SRZN N/A
- UBX N/A
- EPS Growth
- SRZN N/A
- UBX N/A
- EPS
- SRZN N/A
- UBX N/A
- Revenue
- SRZN $10,000,000.00
- UBX N/A
- Revenue This Year
- SRZN N/A
- UBX N/A
- Revenue Next Year
- SRZN N/A
- UBX $33.62
- P/E Ratio
- SRZN N/A
- UBX N/A
- Revenue Growth
- SRZN N/A
- UBX N/A
- 52 Week Low
- SRZN $6.00
- UBX $0.94
- 52 Week High
- SRZN $18.17
- UBX $3.10
- Technical
- Relative Strength Index (RSI)
- SRZN 49.20
- UBX 48.69
- Support Level
- SRZN $11.25
- UBX $1.99
- Resistance Level
- SRZN $12.55
- UBX $2.17
- Average True Range (ATR)
- SRZN 0.97
- UBX 0.22
- MACD
- SRZN 0.11
- UBX -0.05
- Stochastic Oscillator
- SRZN 55.74
- UBX 22.41
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
About UBX Unity Biotechnology Inc.
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.